CHICAGO, July 8, 2011 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Honeywell International Inc. (NYSE: HON), BorgWarner Inc. (NYSE: BWA), United Technologies Corp. (NYSE: UTX), Johnson Controls Inc. (NYSE: JCI) and Mindray Medical International Limited (NYSE: MR).
(Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO)
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Thursday's Analyst Blog:
Honeywell Invests for Global Warming
Honeywell International Inc. (NYSE: HON) is focused on meeting the rising demand for low global warming material used in insulation and aerosols. Through a planned investment of $33 million in its Baton Rouge, La., manufacturing facility, the company will increase the production capabilities of such products. The Baton Rouge facility of Honeywell is a prominent provider of refrigerants in the U.S.
Honeywell will be producing new low-global-warming-potential (GWP) blowing agent and propellant (technical name: HFO-1234ze) on a commercial scale from the upgraded facility. HFO-1234ze production is expected to start in late 2013.
The Baton Rouge facility has been producing beneficial and energy efficient products for its clients for a long time. The investment enables the facility to become a prime provider of next generation technology for meeting low-global-warming aerosol propellants, foam blowing agents and refrigerants. The new products expand Honeywell's existing portfolio of low-global-warming-potential products, helping the company to mitigate a rising worldwide concern in a cost effective manner while fulfilling all the environmental regulations.
The U.S. Environmental Protection Agency has recognized HFO-1234ze to be used safely and sold in foam and aerosols. The material is being used in Europe and Japan. Europe has a large number of consumers.
Based in Morris Township, N.J., Honeywell International Inc. is a Fortune 100 company providing technical and manufacturing support to customers worldwide. It also provides aerospace products and services; control technologies for buildings, homes and industry; automotive products; turbochargers; and specialty materials. Major competitors of Honeywell are BorgWarner Inc. (NYSE: BWA), United Technologies Corp. (NYSE: UTX) and Johnson Controls Inc. (NYSE: JCI).
We maintain a Zacks #1 Rank (short-term Strong Buy recommendation) on Honeywell.
Mindray Acquires Hyssen of China
Mindray Medical International Limited (NYSE: MR), a leading Chinese medical devices company, recently forged an agreement to take a controlling stake in Suzhou Hyssen Electronics Co. Ltd ("Hyssen"). The transaction will not affect Mindray's financial results. The company did not reveal the terms of the deal. Hyssen, based in Suzhou, China, is a leader in automated urine sediment analyzers in the domestic market.
Urine sediment, along with dry chemistry analysis, constitutes urinalysis. Urine sediment analysis is utilized to discover urinary tract and kidney diseases by analyzing bacteria and blood cells in urine samples. Urinalysis, in conjunction with biochemistry analysis and hematology, are the three most frequently used methodologies in the in-vitro diagnostic business.
The urinalysis business, in China, was worth about $155 million in 2010, of which urine sediment analysis constituted approximately 45%, with a growth rate of over 30% per annum.
Mindray plans to extract synergies from the deal by combining its expertise with Hyssen's capability in urine sediment analysis. The company believes that Hyssen's know-how complements its in-vitro diagnostic franchise in urine dry chemistry, biochemistry and hematology.
Mindray represents one of the highest-quality brands in the Chinese healthcare sector and is a bellwether for the medical device industry in that country. The company's competitive advantage in its domestic market is its sales infrastructure, which has provided Mindray significantly better access to China's small and medium-sized hospitals than its competitors.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
About Zacks
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Media Contact
Zacks Investment Research
800-767-3771 ext. 9339
[email protected]
http://www.zacks.com
SOURCE Zacks Investment Research, Inc.
Share this article